Roundup

    Want more claimants? Fill out the form to get free info.
    By submitting this form, I consent that I may be contacted by email and/or phone (including a wireless number) using automated technology, by Adwire Media and/or third-party partners. If I have provided my cell number I also acknowledge that I may be contacted via text message. Message and data rates may apply. My consent is not a requirement for receipt of services.*

    Roundup Criteria

    • Direct exposure to Roundup from work or home use for 5 years or longer
    • Diagnosed with any of the following cancers :
      • Adult T-cell lymphoma/leukemia (T-ATLL)
      • Aggressive NK-cell leukemia (NK-AL)
      • Anaplastic large T/null-cell lymphoma (T/N-ALCL)
      • Blastic mantle cell lymphoma (B- BMCL)
      • Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
      • B-lymphoblastic leukemia (BP-ALL)
      • B-lymphoblastic lymphoma (BP-LBL)
      • B-prolymphocytic leukemia (B-PLL)
      • Burkitt lymphoma (B-BL)
      • Chronic lymphocytic leukemia (B-CLL)
      • Composite lymphoma (CL: % %)
      • Cutaneous CD4-positive small/medium T-cell lymphoma (T-CCD4SML)
      • Cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (T-CCD8ECL)
      • Dendritic/histiocytic neoplasm (DHN)
      • Diffuse follicular lymphoma (B-DFL)
      • Diffuse large B-cell lymphoma (B-DLCL)
      • Diffuse lymphocyte-predominant (HD-LP-D)
      • Diffuse mantle cell lymphoma (B-DMCL)
      • EBV-driven lymphoproliferative disorder (EBVLD)
      • Enteropathy-type T-cell lymphoma (T-EATL)
      • Extranodal marginal zone B-cell Lymphoma (B-EMZL)
      • Follicular lymphoma (B-FL)
      • Hairy cell leukemia (B-HCL)
      • Hepatosplenic T-cell lymphoma (T-HSGDL)
      • Interfollicular (HD-IF)
      • Langherns cell histiocytosis (LCH)
      • Lymphocyte-depleted (HD-LD)
      • Lymphocyte-rich (HD-LR)
      • Lymphoplasmacytic lymphoma (B-LPL)
      • Malignant lymphoma unclassifiable (ML-UC)
      • Mantle cell lymphoma (B-MCL-IS)
      • Mast cell disease (MCD)
      • Mixed cellularity (HD-MC)
      • Mycosis fungoides (T-MF)
      • Nasal NK-T-cell lymphoma (NK/T)
      • NK-cell granular lymphocytic proliferation (NK-GLP)
      • Nodal marginal zone B-cell lymphoma (B-NMZL)
      • Nodular lymphocyte-predominant (HD-LP-N)
      • Nodular mantle cell lymphoma (B-NMCL)
      • Nodular sclerosis (HD-NS)
      • Non-hodgin lymphoma (NHL)
      • Not otherwise specified (HD-NOS)
      • Peripheral gamma-delta T-cell lymphoma (T-PGDL)
      • Peripheral T-cell lymphoma (T-PTCL)
      • Plasma cell dyscrasia (B-PCD)
      • Plasma cell myeloma (B-PCM)
      • Plasmacytoma (B-PC)
      • Post-transplantation lymphoproliferative disorder (PTLD)
      • Primary cutaneous CD30-positive lymphoproliferative disorder (T-PCLPD-CD30)
      • Sezary syndrome (T-SS)
      • Small lymphocytic lymphoma (B-SLL)
      • Splenic diffuse red pulp small B-cell lymphoma (B-SDRPL)
      • Splenic marginal zone B-cell lymphoma (B-SMZL)
      • Subcutaneous panniculitis-like T-cell lymphoma (T-SPTL)
      • T-cell granular lymphocytic proliferation (T-GLP)
      • T-cell lymphoproliferative disorder of childhood, Epstein-Barr virus positive (TLPDC-EBV)
      • T-lymphoblastic leukemia (TP-ALL)
      • T-lymphoblastic lymphoma (TP-LBL)
      • T-prolyrnphocytic leukemia (T-PLL)
      • Unclassifieable B-cell lymphoma (B-UCL)
    • No previous diagnosis
    • No legal representation

    CONTACT US

    We welcome you to contact Mass Torts USA for more information
    about our products and services.